Randomized phase 2a trial assessing a novel septin molecular glue in Alzheimer's disease.

In the verum group, a nominally significant change from baseline was observed for peptides representing A4, a non‐amyloidogenic amyloid precursor protein (APP) processing product, chromogranin‐A (CMGA) and secretogranin‐2 (SCG2), calsyntenin 1 (CSTN1), VGF nerve growth factor inducible (VGF), and phosphatidylethanolamine‐binding protein 1 (PEBP‐1) (Figure S4B ).

also in 7,732 other papers